Effect of Metaxalone 640 mg (M640) on Truck Driving Ability and Cognition Compared to Other Skeletal Muscle Relaxants

Cognitive Impairment Clinical Trial

Official title: Assessment of the Effect of Metaxalone 640 mg (M640) on Truck Driving Ability and Cognition Compared to Other Skeletal Muscle Relaxants: A Prospective, Single-blind, Within-subject Pilot Study

Status Recruiting

Clinical Trial Summary

Every participant will receive active study drug and (tone) 1 comparator, in two (2) stages, one after the other. Each drug will be taken one (1) time after a high fat meal. Vital signs and discussion of medications, illness or injury are considered safety assessments and will be discussed at every visit. There will be (four) 4 visits.

Clinical Trial Description

Every participant will receive active study drug and (one) 1 comparator in two (2) stages, one after the other. Each drug will be taken one (1) time after a high fat meal. Vital signs and discussion of medications, illness or injury are considered safety assessments and will be discussed at every visit. The Screening Visit will be followed by the Baseline (Visit 1) 1-14 days later. At the Baseline Visit participants will be given written tests to measure thinking process. You will also be asked to take a computer driving simulation test. Visits 2 and 3 approximately one (1) week apart will be the dosing days after eating a high fat meal within 30 minutes. The testing from the Baseline Visit will be repeated at four (4) hours and 1.5 hours after dosing with comparator drug. The End of Study safety visit will take place two (2) weeks later. Participants will be given discharge instructions. ;

Related Conditions & MeSH terms

• Cognitive Impairment
• Muscle Hypotonia

• NCT number: NCT06382662
• Study type: Interventional
• Source: Primus Pharmaceuticals
• Contact: Medical Director, Primus
• Phone: 480-483-1410
• Email: jlukban@primusrx.com
• Status: Recruiting
• Phase: Phase 4
• Start date: April 15, 2024
• Completion date: April 15, 2025